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Objective: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aortic pathology with half
of the procedures performed world-wide for indications other than degenerative aneurysm of the descending thoracic
aorta (DTA). This multicenter, prospective study queried perioperative and one-year results of TEVAR using the
commercially available GORE TAG device, in the treatment of acute complicated Type B dissection (cTBD), traumatic
aortic tear (TT), and ruptured degenerative aneurysm (RDA) of the DTA.
Methods: This prospective, non-randomized, literature controlled study included 59 patients; cTBD, n  19; RDA, n 
20; TT, n  20. The primary end-point was the composite of death and total paraplegia in subjects at < 30 days
post-treatment compared with a cohort from current literature. Secondary end-points included adverse events related to
device, procedural and systemic complications, and one-year survival.
Results: All 59 patients had successful endoprosthesis deployment. Fifteen of 19 (79%) patients in the cTBD group had
either rupture or malperfusion syndromes at presentation. Combined 30-day mortality/paraplegia rate was 13.6%
(8/59), with seven (11.9%) deaths (cTBD [3], RDA [3] and TT [1]) and 1 (TT, 1.7%) case of paraplegia. The primary
end-point for the TEVAR cohort was significantly lower (P  .008) when compared with a composite literature control
of 800 patients (combined 30-daymortality/paraplegia of 29.6%). Thirty-day complications of any nature occurred in 48
(81%) patients; 11 (18.6%) were device related, and 43 (73%) experienced one or more systemic adverse events. Six (10%)
patients required additional TEVAR implantations and 3 (5%) patients (one in each pathology group) required
conversion to open surgery. Seventeen (29%) patients had endoleaks of any kind or degree through 30 days; cTBD (7),
TT (2), RDA (8). Nine patients (15.3%) had perioperative strokes with two resultant deaths. Duringmean follow-up time
of 409  309 days, an additional 12 patients died, one patient required open conversion (cTBD), and two patients had
major device related events. Actuarial survival at one year was 66% (range, 52%-77%) for the entire cohort; (cTBD) 79%
(range, 53%-92%), (TT) 79% (range, 53%-92%) and (RDA) 37% (range, 16%-59%). On regression analysis, age at
treatment (1.05 [range, 1.01-1.09]; P  .008) and chronic obstructive pulmonary disease (COPD) (4.3 [range,
1.3-14.4]; P  .02) were predictive of death at one year.
Conclusion: This study confirmed treatment advantages for TEVAR for thoracic aortic catastrophes when compared with
literature-based results of open repair. One-year treatment results indicate a low incidence of graft-related complications.
TEVAR is the preferred initial treatment for the DTA catastrophes studied herein. (J Vasc Surg 2009;50:1255-64.)
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of thoracic endovascular aortic repair (TEVAR; vs. open
surgery) for treatment of intact degenerative aneurysms of
the descending thoracic aorta (DTA).1-4 Yet, unlike endo-
vascular aortic repair (EVAR) for treatment of degenerative
abdominal aortic aneurysm (AAA), TEVAR is potentially
applicable to the spectrum of thoracic aortic pathology.
Indeed, world-wide implants of the sponsor’s “TAG”
endograft (GORE TAG Thoracic Endoprosthesis, W.L.
Gore, Inc., Flagstaff, Arizona, USA) include some 45% of
procedures performed for pathologies other than degener-
ative aneurysm of the DTA.5 Despite the fact that device
engineering considerations might differ among different
pathologies, TEVAR has gained wide acceptance among
surgeons treating, in particular, acute potentially cata-
strophic conditions of the DTA.6-11 Following initial FDA
approval of the TAG device for treatment of intact degen-
erative aneurysm of the DTA in March 2005, a multicenter
clinical trial was designed to test its efficacy in the challeng-
ing DTA pathologies of ruptured degenerative aneurysm
(RDA), traumatic tear (TT), and acute complicated Type B
aortic dissections (cTBD). The trial was conducted at 14
U.S. academic centers (Appendix A, online only); enroll-
ment was completed in February 2007, and results with
one-year follow-up are reported herein.
METHODS
This study is a prospective, non-randomized, literature-
controlled, multicenter trial, which took place between Au-
gust 2005 and February 2007. Enrollment was open to sub-
Table I. Inclusion/exclusion criteria for TAG Complex P
General inclusion criteria
Aneurysmal rupture, aortobronchial/aortoesophageal fistula of
distal aortic dissection, and Subject must be  18 years old
for open surgical repair by the investigator, and Arterial an
lengths as per original TAG device FDA approval)
Disease-specific inclusion criteria
Aneurysmal rupture, aortobronchial fistula, aortoesophageal fistu
Ruptured thoracic aneurysm, or thoracic aortobronchial or aort
Traumatic transection
Complete or incomplete transection of the DTA caused by a tra
Acute complicated distal aortic dissection
Subject diagnosed within 14 days of symptom onset, and
Complicated course, which must include one of the following:
End organ ischemia (ie, malperfusion syndrome)
Refractory hypertension
Rupture or impending rupture
Uncontrollable pain, and
Entire dissection is distal to the left subclavian artery (ie, retrog
Exclusion criteria
4 mm diameter taper between proximal and distal landing zone
compensate for the taper
Not an exclusion criterion for aortic dissection cases. Endopr
Marked tortuosity or stenosis of iliac and/or femoral arteries
Significant thrombus at the proximal or distal landing zones
Mycotic aneurysms
Paraplegia or paraparesis at initial presentation
Participation in another drug or medical device study within on
DTA, Descending thoracic aorta.jects with the following conditions: (1) RDA of the DTA,including aortobronchial or aortoesophageal fistula; (2) TT of
the DTA; and (3) cTBD of the DTA as defined in Table I,
which also details overall inclusion/exclusion criteria. All sub-
jects were deemed candidates for open repair for comparison
to open surgical literature controls. Investigators were allowed
to enroll any patient within the anatomic inclusion criteria.
Eligible subjects underwent pre-treatment extremity neuro-
logic evaluation, non-contrast and contrast-enhanced spiral
computed tomography (CT) with multiplanar reconstruc-
tion. Enrollment was made once patients signed informed
consent. A literature search revealed projected major ad-
vantages for endovascular repairs as detailed in Appendix B
(online only). We conducted a thorough review of peer-
reviewed literature to estimate the incidence of death and
paraplegia through 30 days post-treatment with open re-
pair for complex pathology of the DTA. Manuscripts pub-
lished in the 15 years prior to study initiation (1989-2004)
were selected. We included up to eight manuscripts (19
total) per pathology, each with a minimum total sample size
of 50 subjects per pathology (800 total). The primary
endpoint estimates calculated from these manuscripts were
summarized and presented to a panel of cardiothoracic and
vascular surgeons, which corroborated the results of the
analysis. The protocol was both FDA and individual cen-
ters’ institutional review board-approved with literature
controls, indicating open repair had a 30-day estimated
29.6% mortality/paraplegia risk; the corresponding figure
for TEVAR was 12.6%. Based on pre-study power analysis,
it was estimated that 52 test subjects with primary end-
point data would be required to detect a difference of 17%
logy Trial
TA, or Traumatic transection of the DTA, or Acute complicated
to comply with consent and follow-up and deemed a candidate
y meets pre-defined criteria (seal zone arterial diameters and
ageal fistula
tic event
issection from the distal thoracic aorta is an exclusion criterion)
TA and inability to use devices of different diameters to
sis to be implanted within true lumen.
r of study enrollmentatho
the D
, able
atom
la
oesph
uma
rade d
s of D
osthe
e yeain the composite outcome; 20 subjects were enrolled in
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death and total paraplegia. Lower extremity motor func-
tion post anesthesia, at hospital discharge and at 30 days
was assessed using a standardized scale.12 Secondary end-
points included adverse events, device efficacy, one year
survival, and graft performance data.
Follow-up protocol. Follow-up visits at 30 days, six
months, and annually for five years post-treatment included
clinical and CT exams. Clinical data were reported by
individual centers and monitored independently; the spon-
sor’s core laboratory collected CT scan data. A clinical
events committee (CEC) was assembled to ensure accurate
and consistent reporting of all adverse events (AE), and was
responsible for final adjudication of the data. Adverse
events were classified as major or minor according to pre-
viously defined reporting standards.13 Actuarial survival is
reported with Kaplan-Meier curves. A univariate model was
used to analyze variables associated with death through the
one-year period. Results are reported as [Odds Ratio (95%
confidence interval); P value]. Variables with P  .1 were
then entered into a multivariate Cox regression model and
significant (P .05) results are reported. 2 test was used to
compare nominal data; P .05 was considered significant.
The TAG thoracic endoprosthesis used in this trial has
been previously described.4 Only the surgeon investigators
(ie, not sponsors’ clinical study staff) had access to pre-
procedural imaging. Anatomic inclusion criteria for all pa-
thologies mandated a proximal aortic seal zone between 23
mm and 37 mm and 2 cm in length. Such proximal seal
zone could involve coverage of the left subclavian artery at
the operators’ discretion (but not the common carotid or
innominate arteries) and by protocol had to be free of
dissection or tear. Similarly, distal seal zones of 23 mm to
37 mm diameter and 2 cm in length (not relevant to
Table II. Clinical inclusion criteria for patients in the com
Pt. Malperfusion Organ involved Presenting sym
1 No
2 No
3 Yes Kidney Increased creatin
4 No
5 Yes Extremity Decreased pulse
6 No
7 Yes Bilateral extremity Absent & dimin
8 No
9 No
10 Yes Kidney and extremity Chest and back
11 Yes Extremity Leg ischemia
12 No
13 No
14 No
15 No
16 No
17 No
18 Yes Kidney and mesenteric Extremity ischem
19 Yes Kidney and extremity Increased creatin
HTN, Hypertension.
*Despite medical treatment.dissection cases) were protocol mandated.RESULTS
Demographics and clinical features. A total of 59
patients were enrolled; 19 in the cTBD group (one treated
patient was post-hoc reassigned to the RDA group), 20 in the
TT group, and 20 in the RDA group. As noted in Table II,
clinical inclusion criteria in the dissection group included
patients with renal (4), lower extremity (5), and/or mesen-
teric malperfusion syndromes (1). In total, 15/19 (78%)
dissection patients were treated for rupture (9) and/or malp-
erfusion (7), one of these patients having evidence of both.
Demographic and clinical features are displayed in Table
III. Forty-seven (80%) patients were male. Patients in the
RDA group were significantly (P .0004) older than those in
the cTBD and TT groups. Patients in the RDA group had
significantly higher prevalence of coronary artery disease
(CAD), chronic obstructive pulmonary disease (COPD), hy-
pertension (HTN), and smoking than the TT group. Sum-
mary SVS (Society of Vascular Surgery) risk score for the
entire cohort was 6.2  6.1 (range, 0-24), with significantly
higher values noted for the RDA cohort, and lower values
noted for the TT cohort. For the TT group, mean injury
severity score (ISS) was 36.1 19.9 (range, 1-75).
Operative procedure and reinterventions. All 59 pa-
tients had successful deployment of the endoprosthesis.
Thirty-eight (64%), 14 (24%), and seven (12%) patients had
one, two, and three endoprosthesis placed, respectively, at
initial procedure. On average, patients required 1.7 (range,
1-3), 1.1 (range, 1-2), and 1.7 (range, 1-3) devices in the
cTBD, TT, and RDA groups, respectively. Six subjects
required additional endograft implantation as follows: (1)
(RDA) had a type Ia endoleak on CT done on post treat-
ment day (PTD) one repaired with a proximal extension
and coil embolization of the left subclavian artery on PTD
ted Type B dissection group
s of ischemia
Refractory
HTN Rupture Pain*
Number of
symptoms
Yes No Yes 2
Yes No Yes 2
No Yes No 2
No Yes Yes 2
yanosis No No No 1
Yes No No 1
femoral pulses No No Yes 2
No No Yes 1
No Yes No 1
No No No 1
No No No 1
No Yes No 1
No Yes No 1
No Yes No 1
No Yes No 1
Yes Yes Yes 3
Yes Yes Yes 3
Yes No Yes 3
No No No 1plica
ptom
ine
and c
ished
pain
ia
inethree; (2) (RDA) had a type Ia endoleak on CT performed
rgery.
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imal extension and later successfully by embolization on
PTD 98; (3) (RDA) had a type I endoleak found on CT on
PTD-1 with unsuccessful proximal extension on PTD
seven, a type Ia endoleak was still present on subject’s death
on PTD 121; (4) (TT) had an asymptomatic type I en-
doleak and proximal device compression found at six-month
follow-up visit; proximal endograft extension initially failed
but at one year no further device compression and endoleak
resolution noted; (5) (cTBD) required a graft extension on
PTD 27 for persistent filling of the false lumen distal to the
graft. The patient remains stable at one-year follow-up, albeit
the distal false lumen is still being perfused; (6) (cTBD) has
had a complicated course that included open repair of an acute
(separate event, not device related per imaging performed at
the time of presentation) Type A dissection on PTD 40, a
distal extension with a TAG device to extend the true lumen
for superior mesenteric artery malperfusion and proximal ex-
tension to repair a proximal endoleak on PTD 91. On PTD
307, the patient presented with a contained rupture of the
aortic arch which necessitated open conversion. Three pa-
tients (one in each group) required conversion to open sur-
Table III. Demographics and clinical features
Prima
Acute complicated
dissection n (%)
Trauma
Subjects enrolled 19
Mean age (years) 58.9  14.7 51.
Risk factors
Coronary artery disease 0 (0.0%) 3
Hypercholesterolemia 3 (15.8%) 4
COPD 3 (15.8%) 0
Congestive heart failure 1 (5.3%) 1
Hypertension 18 (94.7%) 8
Cigarette smoking 8 (42.1%) 5
Renal insufficiency 3 (15.8%) 1
Stroke 3 (15.8%) 0
Diabetes 2 (10.5%) 4
Prior thoracotomy 1 (5.3%) 0
Summary SVS Risk Score
(Mean, Std Dev)
6.1 (5.5) 4.8
COPD, Chronic obstructive pulmonary disease; SVS, Society of Vascular Su
Table IV. Primary endpoints through 30 days
Primary pathology
Acute
complicated
dissection n (%)
Traumatic
transection
n (%)
Subjects with successful delivery 19 20
Mortality or paraplegia 3 (16%) 2 (10%)
Mortality 3 (16%) 1 (5%)
Paraplegia 0 (0%) 1 (5%)
1Where risk difference is the proportion of control subjects - proportion of
2P values are based on Chi-square test of independent proportions.gery within 30 days, one because of rupture (cTBD), one dueto an aorto-esophageal fistula (RDA), which was not observed
on imaging done at the time of initial presentation, and the
third due to device compression (TT).
Forty-eight (81%) patients had femoral cutdowns,
while 11 (19%) patients had percutaneous access for deliv-
ery, the use of which was left at the discretion of individual
site investigators. Procedure time averaged 108  51
(range, 45-300) minutes. Procedure time was significantly
shorter (P  .05) for the TT compared with the RDA
group (85  25 vs. 133  68 minutes). Procedural blood
loss averaged 301  375 ml (range, 0-2000 ml). This was
not significantly (P  .6) different between the three
groups. Time in the intensive care unit averaged 9  12
(range, 0.4-56) days. This was significantly greater (P 
.05) for the TT group compared with other two groups
(TT: 18.2 16.7; RDA: 3.9 3.9; cTBD: 4.6 3.6 days).
Hospital stay averaged 16 24 (range, 1-149) days, which
was significantly longer (P  .05) for the TT group com-
pared with the other two groups (TT: 31  36.6; RDA:
7.5  5.1; cTBD: 9.1  7.1).
Primary outcomes. Primary outcomes are detailed in
thology
Overall
total N
P
value
ansection Aneurysm rupture
n (%)
20 59
1.8 76.2  10.7 62.2  19.3 .0004
0%) 7 (35.0%) 10 (16.9%) .01
0%) 9 (45.0%) 16 (27.1%) .08
%) 6 (30.0%) 9 (15.3%) .03
%) 2 (10.0%) 4 (6.8%) .78
0%) 18 (90.0%) 44 (74.6%) .0001
0%) 13 (65.0%) 26 (44.1%) .04
%) 3 (15.0%) 7 (11.9%) .50
%) 2 (10.0%) 5 (8.5%) .20
0%) 5 (25.0%) 11 (18.6%) .50
%) 4 (20.0%) 5 (8.5%) .06
) 7.6 (5.6) 6.2 (6.1) .02
Overall
total n
Open repair
(literature
controls)
Estimated risk
difference (95% CI)1 P value2
rysm
ure
%)
0 59 800
5%) 8 (13.6%) 237 (29.6%) 0.16 (0.07-0.25) 0.008
5%) 7 (12%) 193 (24.1%) 0.5 (0.24-1.0) 0.04
%) 1 (1.7%) 44 (5.5%) 0.31 (0.04-2.2) 0.36
bjects; (0.296-0.136  0.16).ry pa
tic tr
n (%)
20
3  2
(15.
(20.
(0.0
(5.0
(40.
(25.
(5.0
(0.0
(20.
(0.0
(7.2Aneu
rupt
n (
2
3 (1
3 (1
0 (0
test suTable IV. Combined 30-day mortality/paraplegia for the
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died, and one (1.7%) patient (TT group) became paraple-
gic, the single spinal cord complication in the study. The
combined mortality/paraplegia rate for the TEVAR cohort
was significantly less (P  .008) when compared with the
composite literature control of 800 patients (Table IV). Of
the seven early deaths, three occurred in the cTBD group
(two strokes, one aortic rupture), three in the RDA
group (sepsis, stroke, myocardial infarction [MI]) and
one in the TT group (acute respiratory distress syndrome
[ARDS] secondary to pulmonary contusion). Univariate
analysis for variables associated with death at one year is
shown in Table V. Multivariate Cox regression analysis
revealed age [1.05 (95% CI, 1.01-1.09); P  .008] and
COPD [4.3 (95% CI, 1.3-14.4); P  .02] were predic-
tive of death at one year.
Early adverse events. Major adverse events within 30
days occurred in 48 (81%) patients and are detailed in Table
VI. Eleven (18.6%) of these were classified as device-related
events, seven subjects (12%) experienced other procedure
related events, and 43 (73%) subjects experienced one or
more systemic adverse events. Two aortic ruptures oc-
curred in the cTBD group within 30 days. The first patient
presented with chest and back pain on PTD 29. A CT
showed suspected contained rupture, which was managed
with explantation and open conversion, complicated by a
fatal CVA. The second patient had a complicated operative
course, failure to seal the primary tear, and expired from
rupture on PTD one. Partial proximal endograft collapse
occurred in two patients (TT); one was repaired with
Table V. Univariate analysis of variables associated with d
Variable # Obs. included Stand
Gender 59 0
Age (years)* 59 0
Race (Caucasian/Other) 59 1
SVS Summary (Total) 58 0
Pathology group* 59 0
Height (cm) 57 0
Weight (kg)* 59 0
Body surface area 57 0
Smoking history 59 0
ASA 59 0
Number of devices used* 59 0
Coronary artery disease* 59 0
COPD* 59 0
CHF* 59 0
Renal insufficiency 59 0
Diabetes mellitus 59 0
Peripheral vascular disease* 59 0
Back pain symptom 57 0
Chest pain symptom* 57 0
Abdominal pain symptom 57 0
Hypotension symptom 58 0
Procedure time 59 0
Procedural blood loss 58 0
ASA, American Society of Anesthesiology; CHF, congestive heart failure; C
ratio; SVS, Society of Vascular Surgery.
*Included in final multivariate Cox model.placement of a second endograft and one with open con-version. Two patients in the RDA group had other implant
related complications. The first patient had a type Ia en-
doleak identified on PTD two requiring three additional
procedures for resolution. The second patient initially had a
ruptured pseudoaneurysm proximal to a previously placed
TAG device done for TT five months earlier, and presented
with an aortoesophageal fistula on PTD 28. Endoprosthesis
extrusion was noted at explantation during open repair.
Two cTBD patients had major device related events (en-
doleaks) that necessitated revisions. The first patient had
persistent perfusion of the false lumen on PTD 69 despite a
revision procedure done on PTD 40 after the initial im-
plant. The second patient presented with chest and back
pain on PTD 31 and a CT showed an acute Type A
dissection (ie, new ascending aortic tear identified, not
retrograde dissection from graft) that required open sur-
gery with the most proximal TAG device as the distal end of
the surgical reconstruction.
Endoleaks. Seventeen (29%) patients had endoleaks
of any degree or nature through 30 days. Seven endoleaks
occurred in the cTBD, two in the TT, and eight in the RDA
group. Twelve (71%) of the endoleaks were classified as
type I (nine were type Ia and three Ib), four (24%) type II,
and one could not be classified. Of these, six endoleaks were
classified as major events because they resulted in conver-
sion, rupture, or death (Table VI). Two endoleaks occurred
in the cTBD group (type Ia and type II), one in the TT
group (type Ia), and three in the RDA group (all type Ia).
Three patients, all in the RDA group, underwent revisions
at one year
rror P value Odds ratio 95% CI for OR
0.183 1.932 (0.733, 5.095)
.001 1.065 (1.027, 1.105)
0.219 3.535 (0.472, 26.488)
0.127 1.048 (0.987, 1.113)
0.029 1.989 (1.073, 3.685)
0.228 0.976 (0.937, 1.016)
0.062 0.980 (0.959, 1.001)
0.102 0.256 (0.050, 1.313)
0.372 1.507 (0.612, 3.713)
0.174 1.567 (0.820, 2.995)
0.035 1.850 (1.045, 3.274)
0.008 3.591 (1.398, 9.220)
0.006 3.954 (1.498, 10.439)
0.090 2.925 (0.846, 10.114)
0.271 1.859 (0.616, 5.608)
0.190 1.913 (0.726, 5.040)
0.065 2.619 (0.940, 7.297)
0.645 0.809 (0.329, 1.993)
0.013 0.307 (0.121, 0.781)
0.365 0.600 (0.199, 1.811)
0.958 0.962 (0.222, 4.163)
0.256 1.004 (0.997, 1.012)
0.096 1.001 (1.000, 1.002)
fidence interval; COPD, chronic obstructive pulmonary disease; OR, oddseath
ard e
.495
.019
.028
.031
.315
.021
.011
.835
.460
.330
.291
.481
.495
.633
.563
.494
.523
.460
.476
.563
.748
.004
.000
I, condue to persistent endoleak during the early period as above.
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treatment lower extremity function) in the TT group suf-
fered paraplegia. The endograft covered both the left sub-
clavian and the left vertebral artery which arose directly
from the aortic arch. A magnetic resonance imaging (MRI)
on PTD two showed changes consistent with spinal cord
infarction at the T4 level, consistent with the patient’s
physical examination (T4-5 motor and sensory deficits).
Nine patients (15.3%) had strokes during the early study
period. Two patients died within 30 days related to a
stroke. The first patient (cTBD) was an 81-year-old whose
care was withdrawn after a CT confirmed a middle cerebral
artery stroke. The second patient did not regain conscious-
ness postoperatively after implantation of three TAG de-
vices for a ruptured aneurysm. Care was withdrawn after a
CT showed multiple embolic infarcts.
Late events. Twenty-six of 37 (70%) eligible patients
had protocol visits at one year. An additional 12 patients
died at this time interval. A total of three additional pati-
ents have been withdrawn from the study; one in the TT and
two in the RDA group. The patient in the TT group was
removed due open conversion. Of the two patients in the
RDA group that were removed, the first declined appropri-
ate follow-up in the study, and the second was removed for
Table VI. Early and late major adverse events for TAG Co
Earl
Acute complicated
dissection n (%)
Tra
transe
Patients 19
Subjects with one or more major
adverse events
16 (84%) 16
Subjects with one or more major
device-related adverse events
4 (21%) 2
Ruptured aorta 2 (11%)
Endograft infection
Graft collapse 2
Branched vessel occlusion
Endoleak 2 (11%) 1
Other implant related complication
Subjects with one or more major
procedure-related adverse events
3 (16%)
Operative bleeding 1 (5%)
Aortic dissection (within 30 days of
treatment)
2 (11%)
Arterial perforation or rupture
Access site lymphocele,
lymphorrhea, lymphedema
Subjects with one or more major
systemic adverse event
14 (74%) 15
Cardiac 3 (16%) 2
Pulmonary 5 (26%) 11
Renal insufficiency 2 (11%) 3
Cerebrovascular 4 (21%) 4
DVT/PE/coagulopathy 2 (10%) 6
Bowel ischemia
Spinal cord ischemia 1
Other systemic complication 8 (42%) 8
DVT, Deep vein thrombosis; PE, pulmonary embolism.medical co-morbidities precluding follow-up. Conversionto open repair occurred in one patient in the cTBD group.
This patient with a late acute Type A dissection was detailed
above. One late, ultimately fatal endograft infection (RDA)
occurred. An endoleak, related to partial graft collapse, was
identified in one patient (TT) on late follow-up (PTD 87).
This was successfully treated with a proximal endograft
extension. Two additional patients had major device related
events secondary to true/false lumen changes caudal to the
stented segment during late follow-up. The first (cTBD)
had superior mesenteric artery malperfusion, which re-
quired an additional TAG device to further extend the true
lumen. In total there were four late graft events, two in the
same patient. Kaplan-Meier analysis of time to first device-
related major adverse event through one year is presented
in Fig 1, with actuarial tables presented in Appendix C
(online only). Anatomic remodeling in patients treated for
cTBD was favorable with true lumen expansion and decre-
ment in overall aortic diameter. These data have been
separately reported.14 Fig 2 shows a Kaplan-Meier analysis
of survival through one year and actuarial tables are shown
Appendix D (online only). Actuarial survival was 66%
(range, 52%-77%) for the entire cohort; 79% (range, 53%-
92%), 79% (range, 53%-92%) and 37% (range, 16%-59%)
for the cTBD, TT, and RDA groups respectively. A log-
ex Pathology Trial
ts:  30 days Late events
Total
tic
n (%)
Aneurysm
rupture n (%) Total 6-month 12-month
20 59 47 35
) 16 (80%) 48 (81.4%) 17 (36%) 9 (26%) 26
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2 (3.4%)
1 (5%) 1 (1.7%) 1 (2.1%) 1
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2 (10%) 2 (3.4%)
4 (20%) 7 (11.9%)
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2 (3.4%)
3 (15%) 3 (5.1%)
1 (5%) 1 (1.7%)
) 14 (70%) 43 (72.9%) 15 (32%) 9 (25.7%) 26
) 4 (20%) 9 (15.3%) 5 (11%) 5
) 7 (35%) 23 (39.0%) 4 (9%) 4
) 1 (5%) 6 (10.2%) 1 (2.9%) 1
) 1 (5%) 9 (15.3%) 2 (4%) 1 (2.9%) 3
) 1 (5%) 9 (15.3%) 1 (2%) 1
1 (5%) 1 (1.7%) 1 (2.9%) 1
1 (1.7%) 1
) 6 (30%) 22 (37.3%) 8 (17%) 7 (20%) 15mpl
y even
uma
ction
20
(80%
(10%
(10%
(5%)
(75%
(10%
(55%
(15%
(20%
(30%
(5%)
(40%rank test was performed to compare the survival curves
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subjects had shorter survival times than cTBD or TT (P 
.03); however, when controlling for baseline co-morbidities
(COPD, age), the effect of pathology is not significant.
Two patients died on long term follow-up due to aortic
related complications. At one year, freedom from aortic
related death was 84.5% (95% confidence interval [CI]:
72.3-91.6).
DISCUSSION
As anticipated from review of the extant literature,
periprocedural treatment morbidity was significantly in fa-
vor of TEVAR when compared with surgical literature
controls. Both in the composite endpoint approved in the
original protocol design, and in the individual pathologies
(see below), treatment results with TEVAR compare favor-
ably with conventional surgical treatment. For example, a
30-day mortality of 15% for treatment of ruptured DTA
must be considered optimal when compared with corre-
sponding figures of 28% and 27% from two centers of
excellence.15,16 The overall results are furthermore encour-
aging in the context of the relatively early evolution of
Fig 1. Kaplan-Meier analysis of time to first major device related
adverse event.
Fig 2. Kaplan-Meir analysis of survival for TAG Complex Pathol-
ogy Trial.TEVAR design constructs. Pathology-specific TEVARconstructs for complicated type B dissections17 have been
described and are currently being studied in multicenter
clinical trials. The sponsor of the current study has modified
the TAG device to preclude the problems with lesser curve
malapposition and graft collapse; this device will soon be in
clinical trials for both traumatic tear and cTBD.
The validity of historical controls is an anticipated
criticism of single-arm clinical trials. In our study, this was
borne of ethical considerations since the TAG investigators
would (in current practice) preferentially treat the pathol-
ogies studied herein with a TEVAR strategy. Furthermore,
the logical argument that “historical” controls do not
reflect results potentially achievable (in this case with open
surgery) in contemporary practice is refuted by both a
review of current literature and our recalculation of the
original point estimates based on the most recent available
data. Examples include the current International Registry
of Acute Aortic Dissection (IRAD) data for complicated
type B acute dissection treated with TEVAR vs. open
surgey.18,19 A recent IRAD publication reveals a consistent
34% mortality associated with open surgical treatment of
complicated type B dissections.19 In large 2008 multi-
center or meta-analysis publications referable to compara-
tive TEVAR vs. open surgical repair of traumatic aortic tear,
composite death/paraplegia for open surgical treatment
was in the 21%-26% range.7,20 Finally, a recent National
Inpatient Sampling (NIS) study of open surgical treatment
of degenerative DTA reported a “real world’ mortality of
45% for RDA cases.21 Accordingly, the recalculated point
estimates for the historical literature controls reflect results
anticipated in contemporary practice for these challenging
pathologies treated with conventional surgery.
Our study included one-year follow-up data. Not sur-
prisingly, given both the advanced age and the nature of the
pathology in the RDA cohort, late survival was statistically
inferior in this subgroup. Other studies have emphasized
that 30-day outcomes underestimate the total impact of
DTA disease and/or its treatment.22 Survival in the 80%
range at one year for TT and cTBD compares equally or
favorably with the bulk of reported literature.5-7,20,23 Al-
ternatively, one-year survival of 37% in a cohort whose
mean age was 76 years being treated for RDA emphasizes
both respectable salvage in this subgroup, and the impor-
tant reality of attrition in the first year after treatment.
Rarely was this in relation to device specific re-interventions,
although one late open conversion was required in this
group for endograft erosion and infection. Given an antic-
ipated 45% early mortality attending open repair of RDA,21
a one-year survival of 37% after TEVAR repair appears
favorable.
Traumatic aortic tear. Even prior to commercial ap-
proval of a TEVAR device, in the US there has been a rapid
shift to TEVAR repair among surgeons treating TT.7,20,24
Since TT patients are typically victims of multisystem
trauma, associated injuries are the rule and have greatly
impacted treatment results for TT even before the TEVAR
era. Recognizing that prompt operation for aortic repair
was often prohibited by associated injury, a policy of “sur-
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pitalizations were managed with anti-impulse therapy to
“contain” the aortic lesion until treatment of associated
injuries permitted repair of TT.25,26 The obvious flaw in
this strategy was the risk of interval rupture, estimated at
5%-15% in some studies.26 Despite improvements in overall
results with open repair, operative mortality remains signif-
icant even in contemporary reports, ranging from 14%-23%
in several recent meta-analysis and multicenter regis-
tries.7,20,23,24 Virtually all of these reports detail highly
significant reductions in operative mortality in favor of
TEVAR for TT. A single death occurred in our study from
acute respiratory distress syndrome related to pulmonary
contusion, yet the composite end-point of 10% was driven
by a paraplegia complication in one of our TT patients. This
complication is vanishingly rare after TEVAR treatment of
TT; in 2008 publications including two meta-analyses and
one multicenter registry, which in composite detail 715 TT
patients managed with TEVAR, only two cases of spinal
cord ischemic (SCI) complications were detailed.7,20,24
Indeed, these same three studies compare the risk of SCI
with TEVAR vs. open operation for TT and show a statis-
tically significant benefit for TEVAR (0% vs. 5%-7%). In an
American Association for the Surgery of Trauma report, a
single paraplegia case with TEVAR precluded statistical
benefit as paraplegia accompanying open repair was an
admirable 2.9%, essentially half the risk of that reported in
recent meta-analyses.20,24 Our patient who sustained para-
plegia did have left subclavian artery (LSA) coverage re-
cently identified as a risk factor for SCI after TEVAR.27
However, given the typical anatomic proximity to the LSA
origin, complete coverage thereof (complete coverage oc-
curred in four of 20 subjects, 17 of 20 had complete or
partial coverage) will often be required, and in the circum-
stance of TT, most surgeons would not perform antecedent
LSA revascularization. Indeed a systematic review of the
available literature indicates that out of 229 cases of
TEVAR procedures for TT for which procedure detail was
available, 75 (32.7%) included LSA coverage.6 The atypical
nature of our patients’ cord injury (T4 level; complete
motor/sensory) suggests anomalous spinal cord circula-
tion. A relevant consideration is the “degree of poly-
trauma” (as evidenced by ISS) in our patients when com-
pared with other reports. The mean ISS in our study of
36.1  19.9 (range, 1-75) is comparable to that observed
in a large multi-institutional trial (39.4)7 and a large meta-
analysis (39.8).20 Durability considerations referable to
TEVAR are often discussed given the young ages of af-
fected patients. Our patients’ mean age was 51 years old,
slightly older than the mean age in other published large
reports.7,24 Yet, the anatomic circumstances of TT with
focal lesions in an otherwise normal aorta should preclude
considerations of graft migration and component separa-
tion which can be seen with conformational changes in
large DTA. Demetriades et al reported a 14% endoleak rate
after TEVAR but the timing and/or the definition of these
were not specified. Most were successfully managed with a
second endovascular procedure.7 Obviously, attachmentsite endoleaks should be promptly corrected given the
nature of the pathology. The anatomic circumstances of TT
with reference to arch anatomy in young patients presents
as yet unresolved issues with device design. Partial graft
collapse as reported elsewhere did occur in two of our
patients within 30 days; both were asymptomatic and dis-
covered on follow-up imaging. One was treated with sur-
gical conversion and the second with repeat TEVAR, the
latter with a sustained good result. This phenomenon has
been related to both graft oversizing and malapposition on
the inferior curve of the aortic arch.28 Adherence to device
sizing guidelines is crucial to prevent this complication.
Complicated type B dissection. In consideration of
type B dissection, it has long been appreciated that medical
therapy produced equivalent results to surgical graft re-
placement of the aortic entry tear;29 yet cTBD (ie, those
wherein rupture or malperfusion syndromes occur) have
greatly increased mortality when compared with cases
wherein medical therapy suffices.30-33 In such circum-
stances, mortality is increased 3-fold, being 30% in the
original IRAD report.33 “Complication specific” interven-
tions with surgical34,35 and/or endovascular fenestration
procedures36,37 produced reasonable results, particularly
when considered in the context of excessive mortality at-
tending patients with cTBD.30,33 Dake et al introduced
TEVAR as the equivalent of surgical graft replacement of
the proximal entry in 1999, citing 80% resolution of malp-
erfusion syndromes and a 16% mortality in a series of 19
patients.38 Over the past decade, a variety of mostly small,
single center reports, attest to the potential efficacy of
TEVAR for cTBD.8,9,39 A recent cumulative review, which
considered 942 patients treated from 1997 to 2007, re-
ported a 9% mortality and 2% paraplegia rate; however, the
clinical circumstances in which these patients were treated
is unclear;8 registry studies have the same flaw.5
In assessing results of TEVAR for cTBD, two funda-
mental considerations pertain: first, such patients are rela-
tively uncommon. In a recent IRAD study encompassing a
decade of experience, only 125 cTDB patients (ie, 125/
571 22% of type B patients) required intervention in the
acute phase.19 Second, and perhaps more relevant to our
patients, is the heterogeneous spectrum of clinical and
anatomic findings in cTBD patients. Clearly, early peri-
procedural results will vary in accordance with the clinical
severity of the cTBD; to wit 15/19 (79%) of our patients
were treated for rupture and/or malperfusion. The 16%
early mortality (two stroke-related) is within the 3%-21%
range noted in several single center series9,39,40 and cumu-
lative reviews.8
In consideration of comparison of TEVAR vs. open
surgery, early mortality was halved in our patients com-
pared with literature controls. Similar data was reported by
the IRAD investigators. Fattori et al reviewed 125 patients
who required intervention for cTBD; 59 (47%) were
treated with open surgery (56/59 graft replacement of
DTA) and 66 (53%) with an endovascular approach (2/3 of
these TEVAR, remainder endovascular fenestration). Open
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in mortality (odds ratio [OR] 3.4).19
Paraplegia did not occur in our cTBD patients after
TEVAR; the reported incidence of this devastating compli-
cation in single center series ranges from (0%-15%)9,39,40
and may be related to the vagaries of intercostal perfusion
from true vs. false lumen, and the length of DTA coverage.
In the review of Parker et al, paraplegia occurred in 2% of
treated patients.8 The controversy about length of DTA
coverage in aTBD is an issue in need of further study.
Despite the evident focus of resolution of immediate
life-threatening complications, TEVAR for cTBD has an
additional potential benefit, viz. prevention of late aneu-
rysm formation which is known to complicate 40%-50% of
all dissections irrespective of initial medical or surgical
therapy.41 Continued patency of the false lumen has repeat-
edly been associated with such late aneurysm formation.42
In our study, favorable aortic remodeling was observed,
with true lumen expansion, false lumen thrombosis, and
reduction in overall aortic diameters.14 Similar data have
been reported by others.43
Ruptured degenerative DTA. As the concept that
TEVAR compares favorably with open repair in the elective
treatment of intact DTA is now supported by comparative
trial data,1,2,6 an intuitively logical extension would be that
such benefit would extend in a more emphatic way, to
patients with ruptured DTA. The comparative experience
with EVAR for ruptured AAA is both more mature and
corroborative with this position.44,45 The results reported
herein support this logic. A short term mortality of 15% in
our patients is virtually half that reported for open repair
from centers of excellence15,16 and 1/3 that reported in
“real world” NIS data.21 Our favorable early results are also
consistent with emerging longitudinal data in large single
center series.46,47 Despite favorable 30-day data in our
patients, mortality during the first year after treatment was
substantial in this group.
CONCLUSION
Our study confirmed treatment advantages for TEVAR
for thoracic aortic catastrophes when compared with extant
data on conventional surgical repair. Overall treatment
results at one year indicate a low incidence of graft related
complications. While device evolution is hardly complete,
TEVAR will be the principle initial treatment for the pa-
thologies studied herein.
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Site name/principal investigators
Acute complicated
dissection n (%)
Traumatic transection
n (%)
Aneurysm rupture
n (%) Total n
Subjects Enrolled 19 20 20 59
Stanford University Hospital
Daniel Sze, MD 0 (0%) 0 (0%) 1 (5%) 2
Arizona Heart Institute
Venkatesh Ramaiah, MD 4 (21%) 1 (5%) 1 (5%) 6
Northwestern Memorial Hospital
Mark Morash, MD 0 (0%) 0 (0%) 1 (5%) 1
University of Pittsburgh
Jae Cho, MD 0 (0%) 2 (10%) 3 (15%) 5
University of Virginia
Alan Matsumoto, MD 0 (0%) 1 (5%) 0 (0%) 1
Massachusetts General Hospital
Richard P. Cambria, MD 2 (11%) 3 (15%) 4 (20%) 9
Greenville Memorial Hospital
Eugene Langan, MD 0 (0%) 3 (15%) 0 (0%) 3
Emory University Hospital
Karthikeshwar Kasirajan, MD 0 (0%) 1 (5%) 2 (10%) 3
The Vascular Group, Albany, NY
Manish Mehta, MD, MPH 0 (0%) 0 (0%) 1 (5%) 1
University of Florida
Anthony Lee, MD 3 (16%) 3 (15%) 0 (0%) 6
University of Pennsylvania
Joseph Bavaria, MD 6 (32%) 1 (5%) 3 (15%) 10
Baylor College of Medicine
Alan Lumsden, MD 2 (11%) 2 (10%) 0 (0%) 4
University of North Carolina
Mark Farber, MD 2 (11%) 0 (0%) 4 (20%) 6
University of South Florida2 (10%) 0 (0%) 2Martin Back, MD 0 (0%)
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Appendix C (online only)
Time post
treatment (days)
N at risk at
start of interval
N events during
interval*
N censored during
interval*
% Free from major
device related
adverse event 95% CI
Group: Acute Complicated Dissection
0 19 2 (2) 0 (0) 0.895 (0.641, 0.973)
(0-91) 17 2 (4) 2 (2) 0.786 (0.525, 0.914)
(91-182) 13 1 (5) 0 (2) 0.726 (0.459, 0.876)
(182-273) 12 0 (5) 0 (2) 0.726 (0.459, 0.876)
(273-364) 12 0 (5) 0 (2) 0.726 (0.459, 0.876)
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Time post
treatment (days)
N at risk at
start of interval
N events during
interval*
N censored during
interval*
% Free from major
device related
adverse event 95% CI
(364-455) 12 0 (5) 4 (6) 0.726 (0.459, 0.876)
(455-546) 8 0 (5) 8 (14) 0.726 (0.459, 0.876)
Group: Aneurysm Rupture
0 20 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-91) 20 6 (6) 5 (5) 0.649 (0.371, 0.828)
(91-182) 9 0 (6) 3 (8) 0.649 (0.371, 0.828)
(182-273) 6 0 (6) 1 (9) 0.649 (0.371, 0.828)
(273-364) 5 0 (6) 1 (10) 0.649 (0.371, 0.828)
(364-455) 4 0 (6) 1 (11) 0.649 (0.371, 0.828)
(455-546) 3 0 (6) 3 (14) 0.649 (0.371, 0.828)
Group: Traumatic Transection
0 20 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-91) 20 3 (3) 3 (3) 0.835 (0.570, 0.944)
(91-182) 14 0 (3) 1 (4) 0.835 (0.570, 0.944)
(182-273) 13 0 (3) 1 (5) 0.835 (0.570, 0.944)
(273-364) 12 0 (3) 1 (6) 0.835 (0.570, 0.944)
(364-455) 11 0 (3) 3 (9) 0.835 (0.570, 0.944)
(455-546) 8 0 (3) 8 (17) 0.835 (0.570, 0.944)
CI, Confidence interval.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
Appendix D (online only). Report detailed and/or summarized report
Time post
treatment (days)
N at risk at
start of interval
N events during
interval*
N censored during
interval*
%
Survival 95% CI
Group: Acute Complicated Dissection
0 19 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-12) 19 3 (3) 0 (0) 0.842 (0.587, 0.946)
(12-24) 16 0 (3) 0 (0) 0.842 (0.587, 0.946)
(24-36) 16 1 (4) 0 (0) 0.789 (0.532, 0.915)
(36-48) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(48-60) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(60-72) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(72-84) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(84-96) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(96-108) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(108-120) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(120-132) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(132-144) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(144-156) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(156-168) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(168-180) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(180-192) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(192-204) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(204-216) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(216-228) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(228-240) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(240-252) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(252-264) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(264-276) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(276-288) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(288-300) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(300-312) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(312-324) 15 0 (4) 0 (0) 0.789 (0.532, 0.915)
(324-336) 15 0 (4) 1 (1) 0.789 (0.532, 0.915)
(336-348) 14 0 (4) 0 (1) 0.789 (0.532, 0.915)
(348-360) 14 0 (4) 0 (1) 0.789 (0.532, 0.915)
Group: Aneurysm Rupture
0 20 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-12) 20 2 (2) 0 (0) 0.900 (0.656, 0.974)
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Time post
treatment (days)
N at risk at
start of interval
N events during
interval*
N censored during
interval*
%
Survival 95% CI
(12-24) 18 1 (3) 0 (0) 0.850 (0.604, 0.949)
(24-36) 17 0 (3) 0 (0) 0.850 (0.604, 0.949)
(36-48) 17 0 (3) 1 (1) 0.850 (0.604, 0.949)
(48-60) 16 0 (3) 1 (2) 0.850 (0.604, 0.949)
(60-72) 15 1 (4) 0 (2) 0.793 (0.537, 0.917)
(72-84) 14 0 (4) 0 (2) 0.793 (0.537, 0.917)
(84-96) 14 0 (4) 0 (2) 0.793 (0.537, 0.917)
(96-108) 14 2 (6) 0 (2) 0.680 (0.420, 0.843)
(108-120) 12 0 (6) 0 (2) 0.680 (0.420, 0.843)
(120-132) 12 1 (7) 0 (2) 0.623 (0.366, 0.801)
(132-144) 11 0 (7) 1 (3) 0.623 (0.366, 0.801)
(144-156) 10 0 (7) 0 (3) 0.623 (0.366, 0.801)
(156-168) 10 1 (8) 0 (3) 0.561 (0.308, 0.753)
(168-180) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(180-192) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(192-204) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(204-216) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(216-228) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(228-240) 9 0 (8) 0 (3) 0.561 (0.308, 0.753)
(240-252) 9 1 (9) 0 (3) 0.499 (0.254, 0.703)
(252-264) 8 0 (9) 0 (3) 0.499 (0.254, 0.703)
(264-276) 8 0 (9) 0 (3) 0.499 (0.254, 0.703)
(276-288) 8 0 (9) 0 (3) 0.499 (0.254, 0.703)
(288-300) 8 1 (10) 0 (3) 0.436 (0.204, 0.649)
(300-312) 7 0 (10) 0 (3) 0.436 (0.204, 0.649)
(312-324) 7 0 (10) 0 (3) 0.436 (0.204, 0.649)
(324-336) 7 0 (10) 0 (3) 0.436 (0.204, 0.649)
(336-348) 7 0 (10) 0 (3) 0.436 (0.204, 0.649)
(348-360) 7 1 (11) 0 (3) 0.374 (0.158, 0.592)
Group: Traumatic Transection
0 20 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-12) 20 1 (1) 0 (0) 0.950 (0.695, 0.993)
(12-24) 19 0 (1) 0 (0) 0.950 (0.695, 0.993)
(24-36) 19 0 (1) 1 (1) 0.950 (0.695, 0.993)
(36-48) 18 0 (1) 0 (1) 0.950 (0.695, 0.993)
(48-60) 18 1 (2) 0 (1) 0.897 (0.648, 0.973)
(60-72) 17 1 (3) 0 (1) 0.844 (0.591, 0.947)
(72-84) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(84-96) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(96-108) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(108-120) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(120-132) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(132-144) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(144-156) 16 0 (3) 0 (1) 0.844 (0.591, 0.947)
(156-168) 16 0 (3) 1 (2) 0.844 (0.591, 0.947)
(168-180) 15 1 (4) 0 (2) 0.788 (0.528, 0.915)
(180-192) 14 0 (4) 0 (2) 0.788 (0.528, 0.915)
(192-204) 14 0 (4) 0 (2) 0.788 (0.528, 0.915)
(204-216) 14 0 (4) 1 (3) 0.788 (0.528, 0.915)
(216-228) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(228-240) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(240-252) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(252-264) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(264-276) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(276-288) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(288-300) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(300-312) 13 0 (4) 0 (3) 0.788 (0.528, 0.915)
(312-324) 13 0 (4) 1 (4) 0.788 (0.528, 0.915)
(324-336) 12 0 (4) 0 (4) 0.788 (0.528, 0.915)
(336-348) 12 0 (4) 0 (4) 0.788 (0.528, 0.915)
(348-360) 12 0 (4) 1 (5) 0.788 (0.528, 0.915)
CI, Confidence interval.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
